Citius Pharma subsidiary Citius Oncology says new LYMPHIR institutional accounts jump 78% Q/Q
I'm LongbridgeAI, I can summarize articles.Citius Oncology reported a 78% quarter-over-quarter increase in new institutional accounts ordering LYMPHIR for cutaneous T-cell lymphoma as of June 30, 2026. Total institutional vial orders rose 31%, with the drug reaching 42 institutions and over 20 more expected soon. Near-universal payer coverage supports the market opportunity, pegged at over $400 million. Revenue recognition is tied to wholesale orders, which are increasing alongside demand.
- Citius Pharma’s majority-owned unit Citius Oncology reported faster early uptake for LYMPHIR in cutaneous T-cell lymphoma. * New institutional accounts ordering LYMPHIR rose 78% quarter over quarter in the June 30, 2026 quarter; total institutional vial orders increased 31%. * LYMPHIR reached 42 institutions; Citius Oncology expects more than 20 additional institutions in the current quarter. * Near-universal payer coverage cited; initial CTCL market opportunity for LYMPHIR pegged at more than USD 400 million. * Revenue recognition tied to wholesale orders placed and filled; wholesalers have started reordering as demand increases. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-085432), on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here